Non-small cell lung cancer · line 1 · Selpercatinib monotherapy (LIBRETTO-001) — RET fusion+ NSCLC
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | standard |
| Linked regimen | REG-SELPERCATINIB-NSCLC |
| ID | IND-NSCLC-RET-FUSION-1L-SELPERCATINIB |
|---|---|
| Type | Indication |
| Status | reviewed 2026-05-04 | pending_clinical_signoff |
| Diseases | DIS-NSCLC |
| Sources | SRC-LIBRETTO001-DRILON-2020 |
Used By
Algorithms
ALGO-NSCLC-METASTATIC-1L- ALGO-NSCLC-METASTATIC-1L